These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32110554)

  • 1. Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2.
    Liu T; Li S; Wu L; Yu Q; Li J; Feng J; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
    J Hepatocell Carcinoma; 2020; 7():19-31. PubMed ID: 32110554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
    Yang W; Liu J; Hou L; Chen Q; Liu Y
    Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
    J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
    Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
    Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation.
    Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X
    J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853
    [No Abstract]   [Full Text] [Related]  

  • 6. [Shikonin induces hepatocellular carcinoma cell apoptosis by suppressing PKM2/PHD3/HIF-1
    Zhang H; Chen Z; Zhao X; Huo Q; Cheng X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):92-98. PubMed ID: 36856215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
    Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
    Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
    Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms
    Tang JC; Zhao J; Long F; Chen JY; Mu B; Jiang Z; Ren Y; Yang J
    J Cancer; 2018; 9(1):32-40. PubMed ID: 29290767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
    J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma.
    Lu J; Liu SY; Zhang J; Yang GM; Gao GB; Yu NN; Li YP; Li YX; Ma ZQ; Wang Y; Lu CH
    Am J Cancer Res; 2021; 11(7):3575-3593. PubMed ID: 34354861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages.
    Huang B; Wang Q; Jiang L; Lu S; Li C; Xu C; Wang C; Zhang E; Zhang X
    Front Pharmacol; 2022; 13():926945. PubMed ID: 36059938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism.
    Zhou Q; Yin Y; Yu M; Gao D; Sun J; Yang Z; Weng J; Chen W; Atyah M; Shen Y; Ye Q; Li CW; Hung MC; Dong Q; Zhou C; Ren N
    Redox Biol; 2022 Oct; 56():102458. PubMed ID: 36116159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway.
    Zhang J; Zhou J; Xiao S
    Anticancer Drugs; 2020 Oct; 31(9):932-941. PubMed ID: 32282369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
    Li W; Liu J; Zhao Y
    Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells.
    Zeng Z; Lan J; Lei S; Yang Y; He Z; Xue Y; Chen T
    Onco Targets Ther; 2020; 13():11697-11709. PubMed ID: 33244237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
    Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
    Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/SMAD7/TGF-β signaling pathway.
    Li X; Zeng X
    Cell Biol Int; 2020 Feb; 44(2):467-476. PubMed ID: 31617643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
    Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
    Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.